Article
Whole genome analysis on the genetic backgrounds associated with the secondary failure to etanercept in patients with rheumatoid arthritis.
Modern rheumatology - 1 Mar 2017
Funahashi Keiko, Koyano Satoru, Echizen Hirotoshi, Matsubara Tsukasa
Abstract excerpt
OBJECTIVES: Etanercept is effective for the treatment of rheumatoid arthritis (RA). However, some of the patients eventually lose efficacy (secondary failure) despite the absence of neutralizing antibodies. We aimed to explore single nucleotide polymorphisms (SNPs) associated with secondary failure. METHODS: We recruited RA patients given etanercept at 50 mg/week for ≥6 months from the Matsubara Mayflower...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.